HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Negatives Outweigh Positives In Toxic Substances Control Bill, Attorney Says

This article was originally published in The Tan Sheet

Executive Summary

Senate legislation to update the Toxic Substances Control Act shows improvement over a 2010 bill, but its potential benefit does not measure up to the burden it would impose on industry, one attorney says.

You may also be interested in...



Lautenberg Bill Puts Chemical Safety Burden Of Proof On Industry

Legislation introduced in the Senate would update the Toxic Substances Control Act and set the responsibility for chemical safety substantiation squarely on manufacturers' shoulders.

Industry Cautions Against Modeling TSCA Reforms After REACH

While industry, NGOs, legislators and others agree that the 35-year-old Toxic Substances Control Act should be reformed, stakeholders disagree on whether to use the European Union's Registration, Evaluation, Authorization and Restriction of Chemicals as a guide.

“The Clock Is Ticking”: ECHA Launches REACH Awareness Campaign

There is an "urgent" need for companies to work together and share data now that REACH is under way, the European Chemicals Agency (ECHA) stressed at its second stakeholders meeting May 27

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS134511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel